- Home
- PYXS vs ADAP Comparison
PYXS vs ADAP Comparison
Compare PYXS & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- ADAP
- Stock Information
- Founded
- PYXS 2018
- ADAP 2008
- Country
- PYXS United States
- ADAP United Kingdom
- Employees
- PYXS N/A
- ADAP N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- PYXS Health Care
- ADAP Health Care
- Exchange
- PYXS Nasdaq
- ADAP Nasdaq
- Market Cap
- PYXS 66.3M
- ADAP 75.5M
- IPO Year
- PYXS 2021
- ADAP 2015
- Fundamental
- Price
- PYXS $1.22
- ADAP $0.28
- Analyst Decision
- PYXS Strong Buy
- ADAP Buy
- Analyst Count
- PYXS 5
- ADAP 6
- Target Price
- PYXS $9.00
- ADAP $1.52
- AVG Volume (30 Days)
- PYXS 411.8K
- ADAP 1.6M
- Earning Date
- PYXS 05-15-2025
- ADAP 05-13-2025
- Dividend Yield
- PYXS N/A
- ADAP N/A
- EPS Growth
- PYXS N/A
- ADAP N/A
- EPS
- PYXS N/A
- ADAP N/A
- Revenue
- PYXS N/A
- ADAP $179,639,000.00
- Revenue This Year
- PYXS N/A
- ADAP N/A
- Revenue Next Year
- PYXS N/A
- ADAP $52.49
- P/E Ratio
- PYXS N/A
- ADAP N/A
- Revenue Growth
- PYXS N/A
- ADAP 878.53
- 52 Week Low
- PYXS $0.83
- ADAP $0.20
- 52 Week High
- PYXS $5.39
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- PYXS 55.44
- ADAP 51.05
- Support Level
- PYXS $1.20
- ADAP $0.26
- Resistance Level
- PYXS $1.20
- ADAP $0.30
- Average True Range (ATR)
- PYXS 0.08
- ADAP 0.03
- MACD
- PYXS 0.00
- ADAP 0.00
- Stochastic Oscillator
- PYXS 80.85
- ADAP 60.78
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.